Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04561752




Registration number
NCT04561752
Ethics application status
Date submitted
18/09/2020
Date registered
24/09/2020
Date last updated
23/12/2020

Titles & IDs
Public title
A Food Effect Study With ZN-c5 in Healthy Post-Menopausal Subjects
Scientific title
A Randomized, Open-Label, 2-Way Crossover, Single-Dose Food Effect Study of ZN-c5 in Healthy Adult Post-Menopausal Female Subjects
Secondary ID [1] 0 0
ZN-c5-006
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - ZN-c5

Experimental: Treatment Sequence A-B - Participants will take ZN-c5 (150mg), single dose, under fasted conditions, and a week later, will take the same drug under fed conditions to determine the comparative bioavailability of ZN-c5 under these conditions.

Experimental: Treatment Sequence B-A - Participants will take ZN-c5 (150mg), single dose, under fed conditions, and a week later, will take the same drug under fasted conditions to determine the comparative bioavailability of ZN-c5 under these conditions.


Treatment: Drugs: ZN-c5
ZN-c5 is the study drug.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
AUC0-t
Timepoint [1] 0 0
Days 1-4
Primary outcome [2] 0 0
Cmax
Timepoint [2] 0 0
Days 1-4
Primary outcome [3] 0 0
Tmax
Timepoint [3] 0 0
Days 1-4
Primary outcome [4] 0 0
AUC0-infinity
Timepoint [4] 0 0
Days 1-4
Secondary outcome [1] 0 0
Assess the incidence, frequency, and severity of treatment-emergent adverse events (TEAEs)
Timepoint [1] 0 0
Approximately 45 days

Eligibility
Key inclusion criteria
- Healthy female volunteers

- Body mass index (BMI) between > or = 18.0 kg/m2 and < or = 29.9 kg/m2, and a body
weight > or = 50kg and < or = 100kg at Screening

- Non-smoker and must not have used any tobacco products within 2 months prior to
Screening, or if a smoker must be currently (and for the last 2 months prior to
screening) smoking < or = 2 cigarettes or equivalent per week. Current smokers must be
willing to abstain from the use of tobacco and products containing nicotine from 14
days prior to administration of study drug and through the EOS visit.

- No relevant dietary restrictions, and be willing to consume a high calorie, high fat
breakfast and other standard meals provided during the domiciled periods of the study

- Post-menopausal for > or = 24 months. Status will be confirmed through testing of
follicle-stimulating hormone (FSH) levels > or = 40 IU/L at Screening. Participants
that are post-menopausal for < or = 24 months are still potentially eligible, but will
be required to have a negative serum pregnancy test result at Screening and negative
urine pregnancy test result prior to study drug administration.
Minimum age
45 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Any condition likely to affect the participant's ability to consume the standard meal
provided during the domiciled periods of the study, or any condition that may make it
difficult for the patient to comply with the requirement for fasting during the study

- Blood donation or significant blood loss within 60 days prior to the first study drug
administration

- Plasma donation within 7 days prior to the first study drug administration

- Fever (body temperature > or = 38C) or symptomatic viral or bacterial infection or
febrile illness within 2 weeks prior to Screening

- Positive serum pregnancy test at Screening or urine pregnancy test prior to
administration of study drug (for participants who are post-menopausal for < or = 24
months only)

- Positive toxicology screening panel or alcohol breath test

- History of substance abuse or dependency or history of recreational intravenous (IV)
drug use over the last 5 years (by self-declaration)

- Regular alcohol consumption within the 6 months prior to study drug administration,
defined as > 21 alcohol units per week

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/11/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
16/12/2020
Sample size
Target
Accrual to date
Final
20
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Zeno Alpha Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a single-center, randomized, open-label, two-period, 2-way crossover food effect
study to determine the comparative bioavailability of ZN-c5 under fed and fasting conditions,
following single-dose administration of ZN-c5 capsules (150mg).
Trial website
https://clinicaltrials.gov/ct2/show/NCT04561752
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Dimitris Voliotis
Address 0 0
Zeno Alpha Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries